The global organ-on-chip market size was valued at USD 174.95 million in 2025 and is projected to grow from USD 217.20 million in 2026 to USD 1225.84 million by 2034, registering a CAGR of 24.15% during the forecast period from 2026 to 2034. North America dominated the organ on chip market with a market share of 41.2% in 2025.
Organ on chip devices are microfluidic cell culture systems that replicate the structure, function, and physiological responses of human organs on a miniature chip. These platforms combine living human cells, biomaterials, and controlled fluid flow to simulate organ-level activities for drug discovery, disease modeling, toxicity testing, and biomedical research. Organ on chip technology is gaining adoption as it provides more human-relevant data than traditional cell cultures and reduces dependence on animal testing.
The organ on chip market demand is driven by the growing need for predictive preclinical testing and efficient drug development processes. Rising investments in precision medicine, increasing pharmaceutical R&D activities, and regulatory interest in alternative testing methods are supporting adoption. The organ on chip market growth is further driven by advancements in microfluidics, tissue engineering, and personalized disease modeling technologies.
Download a Free Sample To learn more about this report,
Expansion of Organ-on-Chip Technology in Drug Toxicity Testing
The limitations of conventional cell cultures and animal models in predicting human drug responses are encouraging researchers to use organ-on-chip platforms for toxicity assessment. this transition is providing human-relevant models that can reproduce organ functions and drug-induced responses more closely, supporting earlier evaluation of potential toxic effects during preclinical development. for example, the nih tissue chip for drug screening program develops human-cell-based tissue chips that mimic organs such as the heart, kidneys, and lungs to evaluate whether drugs may be safe or toxic in humans.
Development of Vascularized Organ-on-Chip Models
The need to reproduce realistic tissue environments is encouraging researchers to incorporate functional blood-vessel networks into organ-on-chip platforms. this transition is improving the ability of these models to simulate nutrient delivery, drug transport, and interactions between blood vessels and surrounding tissues, supporting more physiologically relevant disease and drug studies. for example, a 2024 scientific reports study developed vascularized cardiac spheroids-on-a-chip to investigate therapeutic toxicity, demonstrating the use of perfusable vascular structures for more realistic cardiac tissue models.
Human-Relevant Disease Models and Microphysiological Systems Drive Market
The limitations of conventional laboratory models create a need for platforms that reproduce human tissue structure and biological responses more closely. fda notes that microphysiological systems can model human physiology and disease states, while nih states that tissue chips are designed to model the structure and function of organs such as the lung, liver, and heart. for example, nih-supported researchers have used a liverchip model to reproduce conditions associated with dormant breast cancer cells becoming active in liver tissue. this need for human-relevant disease models supports procurement of organ-on-chip platforms, human cells, and related laboratory systems.
The advancement of microphysiological systems creates a broader technology base for reproducing organ-level functions under controlled laboratory conditions. a 2024 review indexed in pubmed central reports that more than 60 organs across all 11 human organ systems have been modeled using microphysiological systems. for example, fda researchers have evaluated cardiac microphysiological systems using human stem-cell-derived cardiomyocytes to measure electrophysiology, calcium activity, and contractility. this technological progress supports the supply of specialized organ-on-chip platforms and creates additional applications across pharmaceutical and biomedical research.
Workflow Integration and Technical Expertise Requirements Restrain Market Expansion
Complex integration with existing research workflows can make organ-on-chip systems difficult to incorporate into established laboratory and drug development processes. research reviews identify integration with existing equipment, validation procedures, and data workflows as ongoing challenges, particularly because organ-on-chip platforms require specialized microfluidic and monitoring systems. these integration requirements can increase implementation time and costs, slowing adoption across research and pharmaceutical laboratories.
High technical expertise requirements arise from the need for skills in microfabrication, microfluidics, cell culture, tissue engineering, and data analysis. research literature notes that developing and operating intricate organ-on-chip architectures requires specialized expertise and multidisciplinary knowledge. this skills requirement can make implementation more difficult for laboratories with limited expertise and slow the wider adoption of organ-on-chip technologies.
Organ-on-Chip for Immunotherapy and High-Throughput Screening Offers Growth Opportunities
Organ-on-chip developers, vaccine manufacturers, pharmaceutical companies, and research institutions can use immune-competent tissue models to study vaccine responses and immunotherapies. these platforms create revenue through specialized models, testing services, and research partnerships, with companies such as emulate and mimetas developing human-relevant tissue models for pharmaceutical research.
Organ-on-chip companies, pharmaceutical firms, contract research organizations, and screening laboratories can combine microphysiological models with automated screening workflows. mimetas states that its organoready and organoplate platforms support up to 1,536 tissue models per plate, creating revenue through high-throughput screening services, platform sales, and recurring consumables.
Standardization and Reproducibility Challenges Hinders Growth
Different platforms can use varying chip designs, cell sources, materials, protocols, and measurement methods. a 2024 nature biomedical engineering article notes the need for standards that allow quantitative physiological features in microphysiological systems to be compared and assessed for specific applications. limited standardization can therefore increase validation requirements and make it harder for pharmaceutical customers to compare platforms, slowing technology adoption.
Differences in cell sources, donor characteristics, culture conditions, and chip fabrication can produce variations in experimental results. a nature reviews methods primers guide specifically identifies donor-to-donor, batch-to-batch, and cell-line variability as important considerations in organ-on-chip systems. such variability can increase optimization and validation requirements, making consistent results more difficult to achieve and slowing commercial adoption.
The devices segment accounted for a share of 33.8% in 2025, owing to the increasing adoption of organ-on-chip devices for simulating human organ functions, drug testing, disease modeling, and biomedical research. the growing demand for physiologically relevant models and advanced in-vitro testing platforms further strengthens the segment’s dominant position in the organ on chip market.
The services segment is expected to grow at a cagr of 31.2% during the forecast period, driven by increasing demand for organ-on-chip development, testing, customization, technical support, and research services. the products segment supports organ-on-chip applications through ready-to-use platforms and systems, while the instrument segment contributes through specialized equipment for operating and analyzing organ-on-chip models. the consumables & accessories segment supports ongoing research workflows through culture media, reagents, chips, and other components required for organ-on-chip experiments.
Request Customizationto receive a tailored report.
The liver-on-a-chip segment accounted for a share of 24.8% in 2025 due to the increasing use of liver models in drug toxicity testing, pharmacological research, disease modeling, and evaluation of hepatic responses. the growing demand for physiologically relevant liver models and alternatives to conventional testing methods further strengthens the segment’s dominant position in the organ on chip market.
The heart-on-a-chip segment is expected to grow at a cagr of 32.3% during the forecast period, fueled by increasing demand for advanced cardiac disease modeling, drug screening, toxicity assessment, and personalized medicine applications. the lung-on-a-chip segment supports respiratory disease research and drug testing, while the intestine-on-a-chip segment contributes to studies of intestinal diseases, drug absorption, and host-microbiome interactions. the kidney-on-a-chip segment supports renal disease modeling and nephrotoxicity testing, while the others segment includes additional organ-specific models used across biomedical research and pharmaceutical development.
The drug discovery & development segment accounted for a share of 47.6% in 2025, supported by the increasing use of organ-on-chip models for drug screening, efficacy evaluation, pharmacokinetic studies, and development of safer therapeutics. the growing demand for advanced preclinical testing platforms and alternatives to conventional drug development methods further strengthens the segment’s dominant position in the organ on chip market.
The disease modeling segment is expected to grow at a cagr of 31.6% during the forecast period, propelled by increasing demand for physiologically relevant disease models, growing adoption of personalized medicine approaches, and rising use of organ-on-chip technologies for studying disease mechanisms and treatment responses. the toxicology research segment supports safety and toxicity assessment of drugs and chemicals, while the others segment includes additional applications such as personalized medicine, tissue engineering, and basic biomedical research.
The pharmaceutical and biotechnology companies segment accounted for a 55.4% share in 2025 and is expected to grow at a cagr of 29.5% during the forecast period 2026-2034, driven by increasing adoption of organ-on-chip technologies for drug discovery, preclinical testing, toxicity assessment, and development of advanced therapeutics. the growing need for more predictive and physiologically relevant testing models further strengthens the segment’s dominant position in the organ on chip market.
The academic & research institutes segment supports organ-on-chip research through applications in disease modeling, drug testing, tissue engineering, and basic biomedical studies. the others segment includes additional end users adopting organ-on-chip technologies across specialized research, healthcare, and biotechnology applications.
Speak to an Analystto discuss market opportunities.
The North America organ on chip market accounted for the largest regional share of 41.2% in 2025, driven by strong biomedical research capabilities, increasing investments in drug development, and growing adoption of advanced in-vitro testing technologies. the U.S. organ on chip market is supported by growing federal investment in human-relevant research models. in 2025, nih launched initiatives to expand human-based research technologies, including organ-on-a-chip and microphysiological systems for drug screening, disease modeling, and toxicology. nih also continues to prioritize tissue chips and organ-on-a-chip technologies as alternative research methodologies.
The Canada organ on chip market is supported by national research council initiatives focused on microfluidics and organ-on-chip technologies. the nrc and university of toronto’s centre for research and applications in fluidic technologies develops organ-on-chip systems for drug discovery, disease modeling, and biomedical research, while the nrc’s 2024–2029 strategic plan includes investment in microfluidic fabrication and commercialization of organ-on-chip technologies.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific organ-on-chip market is expected to grow at a cagr of 31.8%, showcasing the fastest-growing regional market, driven by expanding pharmaceutical research, rising investments in biotechnology, and increasing adoption of organ-on-chip technologies for drug discovery and development. In Japan, the japan agency for medical research and development (amed) supports a regenerative-medicine industrialization program that specifically includes the development of organ(s)-on-a-chip systems using cells differentiated from ips cells on chip-based devices. the program aims to develop platforms for evaluating the safety and pharmacokinetics of drug candidates, directly supporting the application of organ-on-chip technology in pharmaceutical research and development. In China, the state administration for market regulation approved gb/t 47486-2026, general technical requirements for vascular chips, on april 30, 2026, with implementation scheduled for may 1, 2027. the standard establishes requirements covering vascular-chip terminology, cell sources, component performance, biological performance, biocompatibility, tissue morphology, barrier function, and testing methods. china has also initiated a national standard project for an organ-on-chip method for nanomaterial toxicity testing, supporting further standardization of organ-on-chip applications.
In South Korea, the korea health industry development institute (khidi) identifies organ-on-a-chip technology as a tool for reducing healthcare r&d costs and improving consistency between non-clinical and clinical trials. korean research institutions are also continuing to develop organ-on-chip technologies, including 2026 research at kaist on micropost-based organ-on-chip platforms for three-dimensional cell environments, drug delivery, and molecular sampling. In India, the government of india stated in august 2026 that the indian council of medical research (icmr) had supported 109 research projects involving non-animal testing methods, including organ-on-chip, 3d tissue models, and computer-based approaches, across 71 institutes and laboratories. the government also reported that bric-instem in bengaluru has dedicated infrastructure for microphysiological systems, including organ-on-chip, organoids, 2d/3d cultures, high-throughput screening, and automation. in addition, an indian institute of science (iisc) bengaluru tender issued in january 2026 sought procurement of a lung-on-chip setup with microfluidics.
The Europe organ-on-chip market accounted for a regional share of 27.3% in 2025, supported by strong life sciences research, increasing demand for alternatives to traditional animal testing, and growing investments in advanced pharmaceutical technologies. In the U.K. organ-on-chip market, the uk health security agency awarded a contract in march 2026 for the purchase of organ-on-chip platforms from emulate, demonstrating direct public-sector procurement of the technology. the u.k. government also announced £22 million in august 2026 for projects aimed at reducing reliance on animal testing and developing human-relevant preclinical models, supporting the broader adoption of organ-on-chip and related technologies.
In the Germany organ-on-chip market, fraunhofer izi-bb highlighted organ-on-chip and microphysiological systems as practical tools for pharmaceutical drug discovery in 2026. its platforms support real-time monitoring of cell viability and metabolic activity for drug efficacy and safety studies, while the institute is developing liver- and tumor-on-chip applications as alternatives to animal models. meanwhile, the France organ-on-chip market is supported by the government-backed pepr med-ooc program, which is developing organs- and organoids-on-chip technologies under france 2030 with a budget of €48.4 million over six years. in june 2026, the program held its second annual scientific meeting with 200 participants, while cea-leti continued developing organoid-on-chip systems with integrated sensors, vascularization, and industrialization capabilities, supporting the expansion of organ-on-chip research and applications in France.
The Middle East and Africa organ on chip market is expected to grow at a cagr of 24.6%, supported by improving biomedical research infrastructure, increasing investments in healthcare innovation, and growing adoption of advanced laboratory technologies. the uae organ-on-chip market is expected to benefit from the country’s growing focus on advanced pharmaceutical research and innovative drug-testing technologies. in february 2026, the emirates drug establishment showcased an organ-on-chip project at world health expo dubai to test drug efficacy using human-relevant models. the agency stated that the technology can improve scientific results, accelerate drug development, reduce reliance on animal models, and support pharmaceutical research and development in the uae.
The Africa organ-on-chip market is expected to benefit from growing biomedical research capabilities and interest in human-relevant models for drug discovery and disease research. in july 2026, a peer-reviewed study on immune organoids for Africa highlighted lymph-node-on-a-chip and other microphysiological systems as platforms for drug screening, vaccine evaluation, precision oncology, and infectious-disease research. the study also proposed capacity-building and frugal bioengineering approaches to expand adoption across African research institutions.
The organ on chip market is moderately fragmented, with biotechnology companies, pharmaceutical companies, life sciences companies, microfluidics technology providers, academic and research institutions, contract research organizations, and specialized organ-on-chip technology developers competing across drug discovery, toxicity testing, disease modeling, personalized medicine, and biomedical research applications. established players compete primarily on model accuracy, biological relevance, reproducibility, microfluidic engineering capabilities, technological innovation, platform scalability, product reliability, application versatility, validation capabilities, regulatory alignment, research and development, and technical support, with leading players such as emulate, inc., cn bio innovations ltd, mimetas, insphero, and tissuse gmbh estimated to account for approximately 45% of the global market based on their technology portfolios, platform capabilities, research partnerships, geographic presence, and competitive positioning.
Emerging and regional players within the organ on chip market ecosystem compete through cost-effective platforms, specialized tissue models, customizable systems, advanced biomaterials, flexible platform designs, application-specific solutions, localized support, rapid innovation, and simplified workflows to address evolving research and drug development requirements and strengthen their market presence. these players also focus on developing specialized tissue models, improving platform reproducibility, and integrating advanced microfluidic technologies to differentiate their offerings and expand their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Cell Line Development Services Market Size, Share, 2034
Base Editing Market Size, Share, Growth, Analysis, Report, 2034
Metagenomic Sequencing Market Size, Share, Growth, Analysis, 2034
Gene Therapy Cell Culture Media Market Size, Share, Growth, 2034
CRISPR-Cas9 Gene Editing Technologies Market Size, Share, 2034
Immunoprotein Diagnostic Testing Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com